Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Trump Says Anthropic No Longer Seen as National Security Threat 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
NEW YORK, Feb. 03, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the first quarter ended December 31, 2015 after the market close on Tuesday, February 9, 2016. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.
| Conference Call & Webcast | |
| Tuesday, February 9 at 5:00pm Eastern Time | |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13629898 |
| Webcast with Slides: | http://public.viavid.com/index.php?id=118193 |
| Replays – Available through February 16, 2016 | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 13629898 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
